Alnylam Pharma (ALNY) Tops Q1 EPS by 98c; reiterates guidance
Tweet
Share
E-mail
Get Alerts ALNY Hot Sheet
Price: $260.51 -2.1%
Revenue Growth %: +15.3%
Financial Fact:
Net loss per common share - basic and diluted: -1.05
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +15.3%
Financial Fact:
Net loss per common share - basic and diluted: -1.05
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q1 EPS of ($0.16), $0.98 better than the analyst estimate of ($1.14). Revenue for the quarter came in at $494.33 million versus the consensus estimate of $428.05 million.
GUIDANCE:
Alnylam Pharma sees FY2024 revenue of $1.4-1.5 billion, versus the consensus of $1.853 billion.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- United Natural Foods (UNFI) Tops Q4 EPS by 8c ; Offers Guidance
- Freeport-McMoRan shares surge as copper hits record $14,694/ton
- HSBC Raises S&P500 Target to 8,100
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
